India · Delayed Price · Currency is INR Neuland Laboratories Statistics
Total Valuation
NSE:NEULANDLAB has a market cap or net worth of INR 236.36 billion. The enterprise value is 238.61 billion.
| Market Cap | 236.36B |
| Enterprise Value | 238.61B |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
| Current Share Class | 12.83M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 11.30% |
| Owned by Institutions (%) | 21.58% |
| Float | 7.28M |
Valuation Ratios
The trailing PE ratio is 64.94 and the forward PE ratio is 56.22.
| PE Ratio | 64.94 |
| Forward PE | 56.22 |
| PS Ratio | 11.68 |
| PB Ratio | 12.61 |
| P/TBV Ratio | 14.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 68.18 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 65.55 |
| EV / Sales | 11.79 |
| EV / EBITDA | 41.32 |
| EV / EBIT | 48.89 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09, with a Debt / Equity ratio of 0.16.
| Current Ratio | 2.09 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 0.52 |
| Debt / FCF | -5.97 |
| Interest Coverage | 26.10 |
Financial Efficiency
Return on equity (ROE) is 21.42% and return on invested capital (ROIC) is 19.05%.
| Return on Equity (ROE) | 21.42% |
| Return on Assets (ROA) | 11.94% |
| Return on Invested Capital (ROIC) | 19.05% |
| Return on Capital Employed (ROCE) | 21.98% |
| Weighted Average Cost of Capital (WACC) | 2.51% |
| Revenue Per Employee | 9.27M |
| Profits Per Employee | 1.67M |
| Employee Count | 1,794 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 2.11 |
Taxes
In the past 12 months, NSE:NEULANDLAB has paid 1.25 billion in taxes.
| Income Tax | 1.25B |
| Effective Tax Rate | 25.56% |
Stock Price Statistics
The stock price has increased by +28.18% in the last 52 weeks. The beta is -0.32, so NSE:NEULANDLAB's price volatility has been lower than the market average.
| Beta (5Y) | -0.32 |
| 52-Week Price Change | +28.18% |
| 50-Day Moving Average | 17,606.72 |
| 200-Day Moving Average | 15,494.70 |
| Relative Strength Index (RSI) | 52.28 |
| Average Volume (20 Days) | 52,966 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:NEULANDLAB had revenue of INR 20.23 billion and earned 3.64 billion in profits. Earnings per share was 283.71.
| Revenue | 20.23B |
| Gross Profit | 10.76B |
| Operating Income | 4.88B |
| Pretax Income | 4.89B |
| Net Income | 3.64B |
| EBITDA | 5.68B |
| EBIT | 4.88B |
| Earnings Per Share (EPS) | 283.71 |
Balance Sheet
The company has 766.70 million in cash and 3.01 billion in debt, with a net cash position of -2.25 billion.
| Cash & Cash Equivalents | 766.70M |
| Total Debt | 3.01B |
| Net Cash | -2.25B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 18.74B |
| Book Value Per Share | 1,461.02 |
| Working Capital | 7.73B |
Cash Flow
In the last 12 months, operating cash flow was 3.47 billion and capital expenditures -3.97 billion, giving a free cash flow of -504.52 million.
| Operating Cash Flow | 3.47B |
| Capital Expenditures | -3.97B |
| Depreciation & Amortization | 794.73M |
| Net Borrowing | 603.66M |
| Free Cash Flow | -504.52M |
| FCF Per Share | n/a |
Margins
Gross margin is 53.18%, with operating and profit margins of 24.12% and 17.99%.
| Gross Margin | 53.18% |
| Operating Margin | 24.12% |
| Pretax Margin | 24.17% |
| Profit Margin | 17.99% |
| EBITDA Margin | 28.05% |
| EBIT Margin | 24.12% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 34.00, which amounts to a dividend yield of 0.18%.
| Dividend Per Share | 34.00 |
| Dividend Yield | 0.18% |
| Dividend Growth (YoY) | 183.33% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.23% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.18% |
| Earnings Yield | 1.54% |
| FCF Yield | -0.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:NEULANDLAB is 21,222.00, which is 15.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 21,222.00 |
| Price Target Difference | 15.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 17.89% |
| EPS Growth Forecast (3Y) | 22.79% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NSE:NEULANDLAB has an Altman Z-Score of 12.34 and a Piotroski F-Score of 5.
| Altman Z-Score | 12.34 |
| Piotroski F-Score | 5 |